ClinicalTrials.gg
RecruitingNCT07815678Updated Sep 14, 2026

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

A Phase 1/2 interventional study of ACCG-2671 and Placebo in Obesity, sponsored by Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics. Recruiting at 6 sites in United States. Open to participants aged 25 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics (part of Structure Therapeutics) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Dec 2025, registered Aug 2026).
  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
25 Years to 75 Years
Sex
All
01

Study summary

This first-in-human study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of ACCG-2671. It will also evaluate the effect of food on the pharmacokinetics, safety, and tolerability of a single dose. Parts 1 and 2 will enroll healthy participants, and Part 3 will enroll otherwise healthy participants with obesity.

Read the detailed description

ACCG-2671 is a nonpeptide dual amylin and calcitonin receptor agonist (DACRA)

This study comprises 3 parts:

Part 1 (Single Ascending Dose [SAD]) will be conducted in healthy participants to assess the safety, tolerability, and PK profile of a single oral dose of ACCG-2671 or -matched placebo (SAD Cohorts 1 through 5).

Part 2 (Food Effect) will be conducted in healthy participants to assess the effect of food intake on the PK, safety, and tolerability of a single oral dose of ACCG-2671 under fasted and fed conditions.

Part 3 (Multiple Ascending Dose [MAD]) will be conducted in otherwise healthy, participants with obesity (BMI ≥ 30 kg/m2) to assess the safety, tolerability, PK profiles of ACCG-2671 or matched placebo administered for 84 days (MAD Cohorts 1 through 5)

Safety Review Committee (SRC) meetings will be held prior to dose escalation for Part 1 (SAD) and Part 3 (MAD) cohorts in the study. The decisions on dose escalation will be based on safety and laboratory data and available PK data from each cohort.

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
  • Amylin
  • Structure Therapeutics
  • Intervention/Treatment
  • Drug: Placebo
  • DRUG:ACCG-2671
03

In context

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

This study's planned enrollment of 164 is above the median of 67 across 9,027 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

This is the only study on the registry with Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Men and women with the following at the time of Screening for Part 1 and 2: ≥25 years and ≤65 years of age and ≥18.0 kg/m2 and \<30.0 kg/m2
  • For Part 3, ≥25 years and ≤75 years of age and BMI ≥30.0 kg/m2
  • For Part 3, receiving a stable dose of an injectable GLP-1RA for ≥3 months, who responded to GLP1RA treatment with stable body weight and no ongoing GLP-1RA-related symptoms or AEs. For the duration of the study, participants must not be planning to change GLP-1RA dose or discontinue GLP-1RA treatment
  • Body weight ≥50.0 kg at time of screening

Exclusion criteria

Exclusion Criteria:

  • For Parts 1 and Part 2: Participants with any medical conditions are excluded from the study.
  • For Parts 1, 2 and 3: participants will be excluded from this study if there is evidence of ANY of the exclusion criteria at the Screening Visit or prior to first dose administration
  • History or presence of significant CV, pulmonary, hepatic, renal, hematological, GI, endocrine, immunologic, dermatologic, psychiatric, or neurological disease, including any acute illness or major surgery within the past 3 months, or any clinical laboratory abnormality determined by the Investigator to be clinically significant
  • Use of any prescription or over-the counter-medication including herbal products, diet aids, vitamins, or hormone supplements (including ) within 10 days or 5 times the apparent elimination half-life of the medication (whichever is longer) before the first study drug administration and throughout the study. Exceptions include injectable GLP-1RA treatment for Part 3, Cohort 2c only and medications used to manage AEs at the discretion of an investigator after consultation with the Sponsor.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
164 participants (estimated)

Study arms

  • Experimental
    Part 1 (SAD)

    Ascending doses of ACCG-2671 administered orally in healthy participants

    Drug: ACCG-2671

  • Placebo comparator
    Placebo Part 1 (SAD)

    Administered orally in healthy participants

    Drug: Placebo

  • Experimental
    Part 2 (Food-effect)

    Single low dose of ACCG-2671 administered orally in healthy participants under fasted and fed state

    Drug: ACCG-2671

  • Experimental
    ACCG-2671 Part 3 (MAD)

    Escalating doses of ACCG-2671 administered orally for 84 days in participants living with obesity (BMI≥30 kg/m2)

    Drug: ACCG-2671

  • Placebo comparator
    Placebo Part 3 (MAD)

    Placebo administered orally for 84 days in participants living with obesity (BMI≥30 kg/m2)

    Drug: Placebo

Interventions

  • DrugACCG-2671

    Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Number of participants with one or more adverse events (AEs) as assessed by CTCAE v5.0

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 24 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  2. Number of participants with one or more serious adverse advents (SAEs) as assessed by CTCAE v5.0

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 24 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  3. Number of participants with one or more treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0

    Time frame: Baseline to Day 21 (Part 2)

  4. Change from baseline in systolic blood pressure

    Time frame: Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  5. Change from baseline in diastolic blood pressure

    Time frame: Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  6. Change from baseline in heart rate

    Time frame: Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  7. Change from baseline in ECG ventricular heart rate

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)

  8. Change from baseline in ECG PR interval

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)

  9. Change from baseline ECG QRS duration

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)

  10. Change from baseline in ECG QT Interval corrected using Fridericia's Formula (QTcF)

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)

  11. Change from baseline in hemoglobin

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  12. Change from baseline in hematocrit

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  13. Change from baseline in thrombocyte count (platelet count)

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  14. Change from baseline in white blood cell (WBC) count

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  15. Change from baseline in prothrombin time

    Time frame: Baseline to day 17 (Part 1, Cohorts 1, 2, and 3); baseline to day 22 (Part 1, Cohorts 4 and 5); baseline to day 21 (Part 2); baseline to day 112 (Part 3)

  16. Change from baseline in international normalized ratio (INR)

    Time frame: Baseline to day 17 (Part 1, Cohorts 1, 2 and 3); baseline to day 22 (Part 1 Cohorts 4 and 5); baseline to day 21 (Part 2); baseline to day 112 (Part 3)

  17. Change from baseline in activated partial thromboplastin time (aPTT)

    Time frame: Baseline to day 17 (Part 1, Cohorts 1, 2 and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  18. Change from baseline in fibrinogen activity

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2 and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  19. Change from baseline in sodium

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  20. Change from baseline in potassium

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  21. Change from baseline in chloride

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  22. Change from baseline in phosphate

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  23. Change from baseline in calcium

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  24. Change from baseline in glucose

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  25. Change from baseline in amylase

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  26. Change from baseline in lipase

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  27. Change from baseline in magnesium

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  28. Change from baseline in albumin

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  29. Change from baseline in lactate dehydrogenase (LDH)

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  30. Change from baseline in creatine kinase

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  31. Change from baseline in creatinine

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  32. Change from baseline in blood urea nitrogen

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  33. Change from baseline in alanine aminotransferase (ALT)

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  34. Change from baseline in total alkaline phosphatase

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  35. Change from baseline in aspartate aminotransferase (AST)

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  36. Change from baseline in gamma-glutamyl transferase (GGT)

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  37. Change from baseline in total bilirubin

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  38. Change from baseline in direct bilirubin

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  39. Change from baseline in indirect bilirubin

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

  40. Number of participants with abnormal urinalysis parameters

    Change from baseline in urinalysis (Including pH, specific gravity, glucose, protein, ketones, blood, nitrites, urobilinogen, and leukocyte esterase)

    Time frame: Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) of ACCG-2671

    Maximum observed plasma concentration of ACCG-2671

    Time frame: Predose through Day 22 (Part 1); predose through Day 18 (Part 2); predose through Day 112 (Part 3)

  2. Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of ACCG-2671

    Plasma AUC0-inf of ACCG-2671 following administration

    Time frame: Predose through Day 22 (Part 1); predose through Day 18 (Part 2)

  3. Area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC0-t) of ACCG-2671

    Plasma AUC0-t of ACCG-2671

    Time frame: Predose through Day 22 (Part 1); predose through Day 18 (Part 2); predose through Day 112 (Part 3)

  4. Area under the plasma concentration-time curve over a dosing interval (AUC0-tau) of ACCG-2671

    Plasma AUC0-tau of ACCG-2671, where tau is the dosing interval

    Time frame: Predose through Day 112 (Part 3)

  5. Time to reach maximum observed plasma concentration (Tmax) of ACCG-2671

    Time to reach the maximum observed plasma concentration of ACCG-2671

    Time frame: Predose through Day 22 (Part 1); predose through Day 18 (Part 2); predose through Day 112 (Part 3)

  6. Terminal elimination half-life (t½) of ACCG-2671

    Terminal elimination half-life of ACCG-2671 in plasma

    Time frame: Predose through Day 22 (Part 1); predose through Day 18 (Part 2); predose through Day 112 (Part 3)

  7. Trough plasma concentration (Ctrough) of ACCG-2671

    Predose plasma concentration of ACCG-2671 at the end of the dosing interval.

    Time frame: Predose through Day 112 (Part 3)

  8. Amount of ACCG-2671 excreted unchanged in urine (Ae)

    Cumulative amount of ACCG-2671 excreted unchanged in urine

    Time frame: Day -1 through Day 7 (Part 1, Cohorts 4 and 5)

  9. Fraction of ACCG-2671 excreted unchanged in urine (Fe)

    Fraction of the administered ACCG-2671 dose excreted unchanged in urine.

    Time frame: Day -1 through Day 7 (Part 1, Cohorts 4 and 5)

  10. Renal clearance (CLr) of ACCG-2671

    Renal clearance of ACCG-2671

    Time frame: Day -1 through Day 7 (Part 1, Cohorts 4 and 5)

07

Study locations

3 of 6 sites recruiting
  • Research Site
    Cypress, California 90630, United States
    Not yet recruiting
  • Research Site
    Lake Forest, California 92630, United States
    Recruiting
  • Research Site
    Decatur, Georgia 30030, United States
    Not yet recruiting
  • Research Site
    Dilworth, Minnesota 56529, United States
    Recruiting
  • Research Site
    Springfield, Missouri 65802, United States
    Not yet recruiting
  • Research Site
    Webster, Texas 77598, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address a specific research question in an approved data sharing request

Supporting information: Study protocol

Time frame: Data sharing requests will be considered beginning 36 months after the study publication (manuscript accepted for publication) and either 1) the product has been granted marketing authorization in at least two regulatory jurisdictions, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Researchers will submit a request containing the research objectives, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). Aconcagua Bio, Inc. does not grant external requests for individual de-identified patient data for the following purposes: Re-evaluating safety and efficacy end points already addressed in the product labelling, Assessing safety or efficacy for an indication in current development Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a panel of external advisors. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2027, 15 months after the start.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2026
First posted
Sep 11, 2026
StartActual
Dec 29, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Apr 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07815678
Responsible party
Sponsor
First posted
Sep 11, 2026
Start date
Dec 29, 2025
Primary completion
Mar 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Sara Ahmed MD
Contact
sara.ahmed@structuretx.com
650-647-0091

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion